This provides a novel mechanism underlying the invasiveness and aggressiveness of PTC promoted by the BRAF V600E and a potential novel therapeutic target for BRAF V600E-harboring thyroid cancer, particularly promising in cases where BRAF V600E inhibitors fail due to drug resistance. The gene discussed is BRAF; the disease is thyroid gland carcinoma.